PMID- 26684028
OWN - NLM
STAT- MEDLINE
DCOM- 20161213
LR  - 20201226
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 3
DP  - 2016 Jan 19
TI  - Adoptive immunotherapy using T lymphocytes redirected to glypican-3 for the 
      treatment of lung squamous cell carcinoma.
PG  - 2496-507
LID - 10.18632/oncotarget.6595 [doi]
AB  - There are unmet medical needs for patients with lung squamous cell carcinoma 
      (LSCC). Therefore, in this study, we explored the antitumor potential of 
      third-generation glypican 3 (GPC3)-redirected chimeric antigen receptor 
      (CAR)-engineered T lymphocytes (CARgpc3 T cells) in tumor models of LSCC. First, 
      we demonstrated by immunohistochemistry (IHC) that GPC3 was expressed in 66.3% of 
      LSCC samples and in 3.3% of lung adenocarcinoma (LAD) samples but not in normal 
      lung tissues. In the presence of GPC3-positive LSCC cells, CARgpc3 T cells were 
      highly activated and increased in number. CARgpc3 T cells could specifically lyse 
      GPC3-positive LSCC cells in vitro. In two established LSCC xenograft models, 
      CARgpc3 T cells could almost completely eliminate the growth of GPC3-positive 
      cells. Additionally, the CARgpc3 T cells were able to persist in vivo and 
      efficiently infiltrate the cancerous tissues. Taken together, these findings 
      indicate that CARgpc3 T cells might be a novel potential therapeutic agent for 
      the treatment of patients with LSCC.
FAU - Li, Kesang
AU  - Li K
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Pan, Xiaorong
AU  - Pan X
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Bi, Yanyu
AU  - Bi Y
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Xu, Wen
AU  - Xu W
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Chen, Cheng
AU  - Chen C
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Gao, Huiping
AU  - Gao H
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Shi, Bizhi
AU  - Shi B
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Jiang, Hua
AU  - Jiang H
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Yang, Shengli
AU  - Yang S
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
FAU - Jiang, Liyan
AU  - Jiang L
AD  - Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong 
      University, Shanghai, China.
FAU - Li, Zonghai
AU  - Li Z
AD  - State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, 
      Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 0 (GPC3 protein, human)
RN  - 0 (Glypicans)
RN  - 0 (Receptors, Antigen, T-Cell)
SB  - IM
MH  - Animals
MH  - Apoptosis
MH  - Blotting, Western
MH  - Carcinoma, Squamous Cell/immunology/metabolism/pathology/*therapy
MH  - Cell Proliferation
MH  - Flow Cytometry
MH  - Glypicans/*immunology/metabolism
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - *Immunotherapy, Adoptive
MH  - Lung Neoplasms/immunology/metabolism/pathology/*therapy
MH  - Mice
MH  - Mice, Inbred NOD
MH  - Mice, SCID
MH  - Receptors, Antigen, T-Cell/metabolism
MH  - T-Lymphocytes, Cytotoxic/*immunology
MH  - Tumor Cells, Cultured
MH  - Xenograft Model Antitumor Assays
PMC - PMC4823050
OTO - NOTNLM
OT  - CAR T cell
OT  - chimeric antigen receptor
OT  - glypican-3
OT  - lung squamous cell carcinoma
COIS- CONFLICTS OF INTEREST Dr. Zonghai Li has ownership interests (including patents) 
      of anti-GPC3 CAR-T. No potential conflicts of interest were disclosed by the 
      other authors.
EDAT- 2015/12/20 06:00
MHDA- 2016/12/15 06:00
PMCR- 2016/01/19
CRDT- 2015/12/20 06:00
PHST- 2015/08/12 00:00 [received]
PHST- 2015/11/21 00:00 [accepted]
PHST- 2015/12/20 06:00 [entrez]
PHST- 2015/12/20 06:00 [pubmed]
PHST- 2016/12/15 06:00 [medline]
PHST- 2016/01/19 00:00 [pmc-release]
AID - 6595 [pii]
AID - 10.18632/oncotarget.6595 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Jan 19;7(3):2496-507. doi: 10.18632/oncotarget.6595.